Niclosamide for Mild to Moderate COVID-19

Niclosamide for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19)

This study will evaluate the antihelmintic drug, Niclosamide, as a potential treatment for mild to moderate coronavirus disease 2019 (COVID-19).

Niclosamide, which has potent antiviral activity against single-stranded RNA viruses including coronaviruses, was proposed as an antiviral during the Severe Acute Respiratory Syndrome (SARS) outbreak in 2002 and has activity including Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) where it was found to inhibit SARS coronavirus, SARS-CoV, in in vitro studies and similarly structured RNA viruses (both in vitro and in vivo). The investigators hypothesize that the antiviral activity of Niclosamide may be extended to COVID-19.

Inclusion Criteria:

• Positive SARS-CoV-2 test by PCR
• No requirement of oxygen supplementation
• Ability to take oral medication

Exclusion Criteria:

• Known allergic reactions to any components of Niclosamide medication
• Participation in another trial or use of any experimental treatment for COVID-19, including chloroquine, hydroxychloroquine, remdesivir, and lopinavir/ritonavir
• Hospitalization or requirement of hospitalization at the time of enrollment